Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Vera Therapeutics, Inc.NASDAQ: VERA
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $132K rose 10.9% year over year, behind the +130.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 48.4% from the prior quarter.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.9% toward the trailing-twelve-month pace of +130.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 468K USD
- Year-over-year change
- +345.7%
- 4-year CAGR
- +27.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 468K | +345.7% |
| FY2024 | 2024-12-31 | 105K | +400.0% |
| FY2023 | 2023-12-31 | 21K | +102.5% |
| FY2022 | 2022-12-31 | (846K) | -580.7% |
| FY2021 | 2021-12-31 | 176K | — |
Depreciation & Amortization vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 depreciation & amortization of $652K is the 8th largest of the 10 companies compared; the peer median is $2.43M.
- Its year-over-year change of +130.4% is the highest of 10, against a peer median of -11.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.32M | +18.9% | +92.7% | — | |
| LTM Mar 2026 | $8.54M | -34.4% | — | 2.3% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $3.08M | +114.9% | +496.0% | — | |
| LTM Mar 2026 | $2.43M | +1.2% | +1.2% | 1.0% | |
| LTM Jun 2026 | $2.25M | -58.5% | +71.0% | 0.5% | |
| LTM Mar 2026 | $1.65M | -23.4% | +19.6% | — | |
| LTM Jun 2026 | $652K | +130.4% | — | — | |
| LTM Mar 2026 | $528K | -25.9% | -17.1% | 6.3% | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| Peer median (excluding VERA) | $2.43M | -11.0% | +56.9% | 4.3% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| Deferred Income Tax | (1.8M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.01M | 8.89M | 11.49M | 20.8M | 37.93M |
| Change in Working Capital | 3.51M | 6.75M | (5.87M) | 2.66M | 22.99M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 475K | 10.61M | (873K) | (3.45M) | 13.91M |
| Other Working Capital | 3.04M | (3.86M) | (5M) | 6.11M | 9.08M |
| Other Non-Cash Items | 4M | 6.67M | (1.84M) | (6.1M) | (2.88M) |
| Operating Cash Flow | (23.71M) | (67.6M) | (92.18M) | (134.68M) | (241.1M) |
| Capital Expenditures | 0 | (62K) | (63K) | (972K) | (630K) |
| Acquisitions (Net) | 796K | 70.49K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (148.49M) | (224.93M) | (711.99M) | (310.45M) |
| Sales of Investments | 0 | 78M | 185.56M | 278.96M | 506.16M |
| Other Investing Activities | (5M) | (70.49K) | 0 | 8.97M | (800K) |
| Investing Cash Flow | (4.2M) | (70.55M) | (39.43M) | (425.03M) | 194.29M |
| Debt Repayment | 4.92M | 19.82M | 24.74M | 0 | 23.34M |
| Common Stock Issued | 51.18M | 86.13M | 115M | 632.54M | 307.48M |
| Common Stock Repurchased | 0 | 0 | 0 | (13K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.22M) | (4.01M) | (6.2M) | (25.85M) | (21.92M) |
| Financing Cash Flow | 53.88M | 101.93M | 133.54M | 606.67M | 308.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.97M | (36.22M) | 1.93M | 46.97M | 262.08M |
| Free Cash Flow | (23.71M) | (67.66M) | (92.24M) | (135.65M) | (241.73M) |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.